CN1413613A - Medicine for resisting microwave and radiation and reducing toxic side effect of radiotherapy and chemotherapy and its preparation method - Google Patents
Medicine for resisting microwave and radiation and reducing toxic side effect of radiotherapy and chemotherapy and its preparation method Download PDFInfo
- Publication number
- CN1413613A CN1413613A CN 02103699 CN02103699A CN1413613A CN 1413613 A CN1413613 A CN 1413613A CN 02103699 CN02103699 CN 02103699 CN 02103699 A CN02103699 A CN 02103699A CN 1413613 A CN1413613 A CN 1413613A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- radiation
- chemotherapy
- microwave
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title claims abstract description 24
- 230000005855 radiation Effects 0.000 title claims abstract description 17
- 231100000331 toxic Toxicity 0.000 title claims abstract description 13
- 230000002588 toxic effect Effects 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 238000002512 chemotherapy Methods 0.000 title abstract description 19
- 238000001959 radiotherapy Methods 0.000 title abstract description 9
- 229940079593 drug Drugs 0.000 title description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 229920002472 Starch Polymers 0.000 claims abstract description 4
- 235000019698 starch Nutrition 0.000 claims abstract description 4
- 239000008107 starch Substances 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 239000000126 substance Substances 0.000 claims description 10
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 238000010992 reflux Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 3
- 238000007654 immersion Methods 0.000 claims description 3
- 238000002386 leaching Methods 0.000 claims description 3
- 239000007940 sugar coated tablet Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 201000011510 cancer Diseases 0.000 abstract description 9
- 206010003549 asthenia Diseases 0.000 abstract description 7
- 230000006870 function Effects 0.000 abstract description 7
- 208000007443 Neurasthenia Diseases 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 210000004233 talus Anatomy 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 description 14
- 210000001772 blood platelet Anatomy 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000001684 chronic effect Effects 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 206010047700 Vomiting Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000001792 thromboblast Anatomy 0.000 description 2
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 1
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102100021906 Cyclin-O Human genes 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229940039750 aconitine Drugs 0.000 description 1
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 1
- 229960001348 estriol Drugs 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000191 radiation effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a medicine for resisting microwave and radiation and relieving toxic and side effects of radiotherapy and chemotherapy of cancer patients and a preparation method thereof. The traditional Chinese medicine raw materials for preparing the medicine and the component dosage are as follows: 10-15 parts of acanthopanax, 3-5 parts of monkshood, 10-15 parts of astragalus and 3-5 parts of dried orange peel. The preparation method of the medicine of the invention is that the alcohol extract paste prepared by the traditional Chinese medicines and the decoction liquid medicine are merged and then are decompressed and condensed into thick paste, and then a proper amount of starch is added to prepare the traditional Chinese medicine compound. The medicine of the present invention has the functions of raising the number of leucocyte and platelet of patient, improving immunity, relieving bad neurasthenia, protecting microwave and radiation operator and relieving the toxic side effect of radiotherapy and chemotherapy of cancer patient.
Description
Technical field
The present invention relates to a kind of anti-microwave, radiation effects and alleviate that cancer patient is put, the medicine of chemical therapy toxic side effect, be specifically a kind of be the Chinese patent medicine of feedstock production with the Chinese herbal medicine.The invention still further relates to the preparation method of this medicine.
Background technology
Microwave and radiation by internationally recognized be the physics public hazards.Symptoms such as hemopoietic function reduction, neurasthenia, work efficiency and physically-draining can appear in the operating personnel of long-term contact microwave and ionizing radiation.Cancerous protuberance is the highest disease kind of domestic and international mortality rate, and put, chemotherapy is treatment cancerous protuberance patient must be through means.But put, chemotherapeutic treatment also produces serious toxic and side effects to the whole body normal physiological function when killing cancerous cell, go down and occur intensively feeling sick and reaction such as inappetence as leukocyte and blood platelet reduction, immunologic function, obviously influence put, the therapeutic effect of chemotherapy.At present, lack both at home and abroad that protection various microwave telecommunication devices and radar microwave operating personnel and alleviating put, the medicine of chemical therapy toxic side effect, some chemical agent that adopts all can cause other side effect, though can alleviate the leucocytes reduction after the radiation and improve clinical symptoms as chemical medicine estriol, can cause that sexual function reduces and side effect such as menoxenia.The improvement of application Chinese herbal medicine is put, chemical therapy toxic side effect once aroused considerable attention, but most of research lacks detailed clinical report, and therapeutic effect is also undesirable.
Technology contents
Technical problem to be solved by this invention provides a kind of health that can protect microwave and radiation operating personnel, can alleviate again put, chemical therapy toxic side effect De Guang Spectrum, multi-functional, avirulent medicine, and the preparation method of this medicine.
Though microwave is with radiation and put, paathogenic factor such as chemotherapy is different, can cause identical globality reactive state.Its clinical manifestation is that hemopoietic function reduces, immunologic function weakens and the neurasthenia occurs.Most patients belong to deficient syndrome through differential diagnosis in tcm, especially based on YANG asthenia disease.The present invention controls principle according to the differential diagnosis in tcm opinion, takes nourishing YIN and invigorating YANG, the strengthening the body resistance rule of treatment, is mixed with Chinese medicine compound.
Medicine of the present invention is formed (consumption is a weight portion) by following component:
10～15 parts of Shu Wujia,
3～5 parts of Radix Aconiti Lateralis Preparatas,
10～15 parts of the Radixs Astragali,
3～5 parts of Pericarpium Citri Reticulataes.
The effective ingredient of this Chinese medicine compound component
| Title | Effective ingredient |
| Radix Et Caulis Acanthopanacis Senticosi Radix Aconiti Lateralis Preparata Radix Astragali Pericarpium Citri Reticulatae | Biological alkali, Saponin oil, polysaccharide and cardiotonic glycoside hypaconitine, biological alkali such as aconitine; Eicosadienoic acid, oils and fats choline such as Lin Zhi Suan Calcium, betanin, leaf alkali, aminoacid volatile oil, flavone, inositol, vitamin B 1Deng |
The preparation method of medicine of the present invention is:
1. Radix Et Caulis Acanthopanacis Senticosi reclaims ethanol then with 70～80% alcohol reflux secondaries, receives dried cream amount 3～5%; 2. Radix Aconiti Lateralis Preparata is got the Radix Aconiti Preparata sheet, adds 2～6 times of 70～80% ethanol, refluxes 2 hours, receives immersion, and medicinal residues add 2～5 times of 70～80% ethanol again, refluxes 1 hour, collects concentrated solution; 3. Radix Astragali decoction pieces adds 10～15 times in water, successively decocts secondary, and each 1 hour, the leaching medicinal liquid; 4. Pericarpium Citri Reticulatae places extractor, adds 10～15 times in water, is heated to and boils, and keeps little boiling, and oil is extracted to the greatest extent, and oil yield is about 0.2～0.6%, keeps the Pericarpium Citri Reticulatae medicinal liquid; 5. above-mentioned alcohol extraction cream and decocting medicinal liquid are merged, concentrating under reduced pressure becomes thick paste, adds 1～30% starch and makes granular or sugar coated tablet.
Medicine of the present invention has the following advantages:
1. broad spectrum activity (comprises microwave operating personnel 296 examples according to a large amount of clinical experiments, chronic radiation disease patient's 55 examples, cancer radiation patient 137 examples, cancer chemotherapy patient 55 examples), prove this Chinese patent medicine to microwave operating personnel health, chronic radiation disease patient and put, patients undergoing chemotherapy all has significant protective effect and therapeutical effect, promptly has the advantage of broad spectrum activity;
2. multi-functional according to animal experiment study and clinical experiment result, prove that the present invention has the immune indexes of improvement, improve the hematopoietic stem cell ability, improve brain function and the treatment function that alleviates aspects such as free radical illeffects;
3. high curative effect is according to clinical trial certificate, and this Chinese patent medicine has tangible curative effect.
Clinical symptoms is improved effective percentage rate
| Personnel | Leukocyte platelet neurasthenia symptom |
| Microwave operating personnel 296 examples | ??93.8????90.9????67.7 |
| Chronic radiation disease patient's 55 examples | ??87.5????81.3????70～98.6 |
| Radiotherapy patient 137 examples | ??94.2????97.6????94 |
| Patients undergoing chemotherapy 55 examples | ??96.4????95.8 |
The specific embodiment
At first take by weighing raw material by following proportioning:
6.5 kilograms of Ci slender acanthopanax Gen Stems,
2.0 kilograms of Radix Aconiti Lateralis Preparatas (Radix Aconiti Preparata),
6.0 kilograms of the Radixs Astragali,
2.0 kilograms of Pericarpium Citri Reticulataes;
Then that Ci slender acanthopanax Gen Stems is dry sliced, with 78% alcohol reflux secondary, reclaim ethanol, receive dried cream amount about 5%; With the Radix Aconiti Preparata section, add 4 times of 80% ethanol, refluxed 2 hours, collect immersion, medicinal residues add 3 times of 80% ethanol again, reflux 1 hour, collect concentrated solution; Get Radix Astragali decoction pieces, add 10 times in water, successively decoct secondary, each 1 hour, the leaching medicinal liquid; Get Pericarpium Citri Reticulatae and place extractor, add 11 times in water, be heated to and boil, keep little boiling, oil is extracted to the greatest extent, obtain the Pericarpium Citri Reticulatae medicinal liquid.At last, above-mentioned four kinds of filtrates and unguentum are merged, concentrating under reduced pressure becomes thick paste, adds 1% starch and makes 14000 of sugar coated tablets.
Medicine of the present invention is the best prescription that filters out through a large amount of zooperies, and through animal subacute toxicity test proof avirulence.543 routine clinical trials prove; it has obvious raising patient leukocyte, platelet count; improve adverse neurological symptoms such as the immune indexes and the Jian Qing Evil heart, vomiting, inappetence, insomnia; protection microwave and radiation operating personnel's health, and alleviate obviously that cancer patient is put, the usefulness of chemical therapy toxic side effect.The overheated journey of concrete clinical trial is described below:
1. the overheated journey of clinical trial that cancer patient is put, chemical therapy toxic side effect is administered
Test hospital comprise air force general hospital, Navy General Hospital, 309 hospitals, Beijing hospital attached to a medical college, Fengtai railway hospital general, Wuhan City No.1 Hospital, Affiliated Hospital of Changchun Bethune medical university, Harbin Affiliated Hospital of medical university, etc. eight tame hospitals.Subjects is for acceptance is put, the patient of chemotherapy.Chemotherapy adopts composite treatment, and medicine comprises fluorouracil, CCNU, vinblastine etc.Radiotherapy adopt degree of depth X-ray or
60The Co ray.Patient accept to put, take in the chemotherapy medicine of the present invention (high agent or the tablet grown, every day, dosage was equivalent to crude drug 40 grams) until put, end of chemotherapy.Observation index is various main suits, end hemogram (leukocyte and platelet count), leukocyte differential count slightly.Counting is weekly in beginning forward and backward and therapeutic process, to compare therapeutic effect.The part patient is carried out the immune indexes inspection.Chemotherapy cancer patient totally 55 people in this clinical trial.Can not adhere to that because of occurring feeling sick all the other all adhere to finishing the whole course of treatment the treatment except that one.Patient generally react add the untoward reaction that chemotherapy causes behind the medicine of the present invention (as feel sick, fatigue, vomiting etc.) all obviously alleviate.Patient's leukocyte and platelet its meansigma methods under the chemotherapy cumulative function that continued for five weeks is not seen reduction.Treatment proleukocyte weighted mean value is 6246 ± 2034/mm
3, be 6547 ± 2370/mm after the treatment
3Treatment thromboblast weighted mean value is 14.1 ± 5.8 ten thousand/mm
3, be 13.7 ± 5.2 ten thousand/mm after the treatment
3All maintain normal range.And according to 127 routine hepatocarcinoma patients of bibliographical information obvious inhibition the person (＜3500/mm of leukocyte in chemotherapy process
3) accounting for 25% of whole cases, serious digestive tract reaction person accounts for 6%.Above comparative descriptions medicine of the present invention has the effect of tangible control chemotherapy side effect.
The cancer patient who participates in medical treatment radiotherapy side effect of the present invention clinical trial is totally 137 people.Can not adhere to that because of urticatia medicamentosa occurring all the other patients all adhere to finishing the whole course of treatment the treatment except that one.Patient generally reacts to add and feels normal behind the medicine of the present invention, and radiotherapy causes that untoward reaction (as insomnia, inappetence, weak etc.) main suit person has 5 examples, accounts for 5%.Patient's leukocyte and platelet meansigma methods are still in normal range under the chemotherapy cumulative function that continued for five weeks.Treatment proleukocyte weighted mean value is 7966 ± 3260/mm
3, be 6129 ± 2007/mm after the treatment
3Treatment thromboblast weighted mean value is 15.1 ± 6.8 ten thousand/mm
3, be 14.4 ± 4.3 ten thousand/mm after the treatment
3And according to 350 routine hepatocarcinoma patient radiotherapy results of bibliographical information, leukopenia (＜3000/mm
3), accounting for 13.7% of whole cases, nauseating responder accounts for 29.4%, and the vomiting reaction person accounts for 8.1%, and inappetence accounts for 31.1%.Above comparative descriptions medicine of the present invention has the effect of tangible control radiotherapy side effect.
The object of participating in medical treatment chronic radiation disease of the present invention clinical trial is for long-term contact radioactive substance and hemogram abnormity occurs and staff that vegetative nerve is unable, totally 55 examples.Above patient takes medicine paste nourishing agent of the present invention, and every day, dosage was equivalent to crude drug 40 grams, serve on 2～3 months (course of treatment) oral 2～3 times of every day, other Chinese and western drugses of forbidding during the treatment.Result of the test shows, 40 routine low leukocyte counts person (＜4000/mm
3) leukocyte returns to normal range (＞5000/mm after the medication
3) person's 33 examples (accounting for 82.5%); Higher the person (＜11000/mm of 8 routine leukocyte
3) leukocyte returns to normal range (＞10000/mm after the medication
3) person's 7 examples (accounting for 87.5%); The vegetative nerve function improvement reaches 70～98.6% respectively.
Microwave damage therapeutic effect subjects is on the low side for often being subjected to radar and microwave radiation and neurasthenia main suit, leukocyte and platelet occurring, and the operating personnel of symptom such as blood pressure is on the low side.Subjects is divided into two groups: take medicine group and matched group.The group of taking medicine is taken medicine of the present invention, and every day, dosage was equivalent to crude drug 40 grams; Matched group is taken the identical comfort medicine of profile.Took medicine continuously 28 days or 45 days.The contrast of indexs such as the forward and backward main suit of carrying out, leukocyte and the platelet of taking medicine, some of the staff carry out immune indexes and measure.Result of the test shows that the group of taking medicine 81 calamitas urinae hominis's cells obviously increase and keep the person of stablizing to account for 93.8% of total number of persons; The group of taking medicine 143 philtrum platelet obviously increase and keep the person of stablizing to account for 90.9% of total number of persons; The neurasthenia symptom improver accounts for 67.7% of total number of persons.Learn computational analysis by statistics, above-mentioned three indexs of the group of taking medicine are improved degree has significant difference (p＜0.01～0.05) than matched group.
Claims (2)
- An anti-microwave, radiation and alleviating put, the medicine of chemical therapy toxic side effect, it is characterized in that it is the medicament of being made by the following weight proportion raw material: 10～15 parts of Radix Et Caulis Acanthopanacis Senticosis, 3～5 parts of Radix Aconiti Lateralis Preparatas, 10～15 parts of the Radixs Astragali, 3～5 parts of Pericarpium Citri Reticulataes.
- The described anti-microwave of claim 1, radiation and alleviating put, the preparation method of the medicine of chemical therapy toxic side effect, it is characterized in that Radix Et Caulis Acanthopanacis Senticosi with 70～80% alcohol reflux secondaries, reclaims ethanol then, receive dried cream amount 3～5%; Radix Aconiti Lateralis Preparata is got the Radix Aconiti Preparata sheet, adds 2～6 times of 70～80% ethanol, refluxes 2 hours, receives immersion, and medicinal residues add 2～5 times of 70～80% ethanol again, refluxes 1 hour, collects concentrated solution; Get Radix Astragali decoction pieces, add 10～15 times in water, successively decoct secondary, each 1 hour, the leaching medicinal liquid; Get Pericarpium Citri Reticulatae and place extractor, add 10～15 times in water, be heated to and boil, keep little boiling, oil is extracted to the greatest extent oil yield 0.2～0.6%; At last, above-mentioned alcohol extraction unguentum and decocting medicinal liquid are merged, concentrating under reduced pressure becomes thick paste, adds 1～30% starch and makes granular or sugar coated tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021036993A CN1171609C (en) | 2002-02-19 | 2002-02-19 | Medicine for anti-microwave, radiation and reducing toxic and side effect of radiotherapy and chemotherapy and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021036993A CN1171609C (en) | 2002-02-19 | 2002-02-19 | Medicine for anti-microwave, radiation and reducing toxic and side effect of radiotherapy and chemotherapy and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1413613A true CN1413613A (en) | 2003-04-30 |
| CN1171609C CN1171609C (en) | 2004-10-20 |
Family
ID=4739865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021036993A Expired - Fee Related CN1171609C (en) | 2002-02-19 | 2002-02-19 | Medicine for anti-microwave, radiation and reducing toxic and side effect of radiotherapy and chemotherapy and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1171609C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148038A (en) * | 2015-10-28 | 2015-12-16 | 粘琦玉 | Traditional Chinese medicine pills for treating adverse reactions after CT examination and preparation method |
| CN105902607A (en) * | 2016-06-29 | 2016-08-31 | 李翠锦 | Fiveleaf gynostemma herb-containing traditional Chinese medicine composition |
-
2002
- 2002-02-19 CN CNB021036993A patent/CN1171609C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105148038A (en) * | 2015-10-28 | 2015-12-16 | 粘琦玉 | Traditional Chinese medicine pills for treating adverse reactions after CT examination and preparation method |
| CN105902607A (en) * | 2016-06-29 | 2016-08-31 | 李翠锦 | Fiveleaf gynostemma herb-containing traditional Chinese medicine composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1171609C (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1150928C (en) | Medicine for curing cancers and its preparation method | |
| CN102727687B (en) | Medicine treating chronic fatigue syndrome and its application | |
| CN109908194A (en) | A kind of drug and preparation method thereof for treating acute/chronic pharyngitis | |
| CN102727787A (en) | Drug with characteristics of rapid transaminase lowering and live protection | |
| CN1171609C (en) | Medicine for anti-microwave, radiation and reducing toxic and side effect of radiotherapy and chemotherapy and its preparation method | |
| CN101347543A (en) | Chinese medicine compound and preparation method thereof | |
| CN1682837A (en) | Medicine for regulating blood fat and its preparing method | |
| CN1730090A (en) | Chinese traditional medicinal composition for treating hepatitis and process for preparing the same | |
| CN107823487B (en) | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof | |
| CN103040983B (en) | Traditional Chinese medicine for preventing and/or treating premonitory apoplexy and preparation method thereof | |
| CN113827652A (en) | Traditional Chinese medicine composition for treating migraine and preparation method and application thereof | |
| CN1931300A (en) | Externally applied medicine for treating women's dysmenorrhea | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN104940516A (en) | Traditional Chinese medicine composition for treating chronic aplastic anemia, and preparation method and application thereof | |
| CN1141965C (en) | Medicine for treating heart disease | |
| CN1042495C (en) | Medicine for benefitting Qi, removing cancer and raising leucocyte and its prepn. | |
| CN1056760C (en) | Narcotic capsule and its preparing process | |
| CN102846965A (en) | Traditional Chinese medicine preparation capable of resisting HIV and improving immunity and preparation method of traditional Chinese medicine | |
| CN1059583C (en) | Oral liquid of Chinese medicine for deficiency syndrome | |
| CN1314410C (en) | Chinse medicinal formulation for health-care and heptitis treatment | |
| CN102727730B (en) | Traditional Chinese medicinal compound preparation for treating male infertility and its preparation method | |
| CN102488825A (en) | Traditional Chinese medicine composition for treating beriberoid pyretic arthralgia and application of traditional Chinese medicine composition | |
| CN1323628A (en) | Kidney-invigorating and male sexual function improving traditional Chinese medicine prepn. | |
| CN101584839A (en) | Chinese medicament for treating acute and chronic cholecystitis | |
| CN1242198A (en) | Traditional Chinese medicine capsule for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20041020 Termination date: 20110219 |